Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

131.50 -0.26 (-0.20%)
Official Closing Price Updated: 4:15 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
From GeneDx
Via Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From GeneDx
Via Business Wire
The Markets Are Ignoring Risk, But That Does Not Mean You Should...
It is Fall clean-up time. Sell lagging and sagging companies. 
Via Talk Markets
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
The company provides sequencing tools to help diagnose children with rare diseases. 
Via Investor's Business Daily
Expert Ratings For GeneDx Hldgs
 
Via Benzinga
The Latest Analyst Ratings For GeneDx Hldgs
 
Via Benzinga
GeneDx to Participate in Fall Investor Conferences
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
From GeneDx
Via Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
7 Small-Cap Stocks With Massive Potential Returns
Explore these small-cap stocks with high potential in health care, REITs, entertainment, hardware, finance, and distribution industries. 
Via InvestorPlace
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
From GeneDx Holdings Corp.
Via GlobeNewswire
Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
From GeneDx Holdings Corp.
Via GlobeNewswire
Over $4M Bet On ProFrac Holding? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
GeneDx to Participate in Upcoming Investor Conferences
From GeneDx Holdings Corp.
Via GlobeNewswire
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
 
Via Benzinga
Gold Down Over 2%; 3M Profit Beats Expectations
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Eli Lilly Increases FY24 Outlook, Joins Brinker International, Zebra Technologies, 3M And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today! 
Via InvestorPlace
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance
GeneDx reports quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents by 50.75%. The company reported quarterly sales of $62.422 million which beat the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.